Adma Biologics Inc (NASDAQ:ADMA) finished Friday with an addition of $0.04 to close at $3.58, an upside of 1.13 percent. An average of 1,168,820 shares of common stock have been traded in the last five days. There was a gain of $0.07 in the past week, and it reached a new high 24 times over the past 12 months. The last 20 days have seen an average of 1,614,920 shares traded, while the 50-day average volume stands at 2,242,626.
ADMA stock has decreased by -2.19% in the last month. The company shares reached their 1-month lowest point of $3.43 on 09/25/23. With the stock rallying to its 52-week high on 08/15/23, shares of the company touched a low of $2.24 and a high of $4.65 in 52 weeks. It has reached a new high 6 times so far this year and lost -7.73% or -$0.30 in price. In spite of this, the price is down -23.01% from the 52-week high.
Insider Transactions
ADMA stock investors should be aware that Adma Biologics Inc (ADMA) stock had its last reported insider trading activity 39 days ago on Aug 30. In this transaction, the insider spent $5,544,737. President and CEO, Grossman Adam S, disposed of 250,000 shares at a price of $4.15 on Aug 18. The insider now owns more than $1,038,350 worth of shares. Prior to that, EVP, CFO LENZ BRIAN went on to Sale 178,184 shares at $4.45 each on Aug 16. An amount of $793,400 was transacted.
Valuation Metrics
Adma Biologics Inc (ADMA) stock’s beta is 0.82. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.87, the price-to-book (PB) ratio at 5.48.
Financial Health
The quick ratio of Adma Biologics Inc for the three months ended June 29 was 2.49, and the current ratio was 6.35, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.03 and a total debt to equity ratio of 1.03 for the quarter ending June 29. Its gross profit as reported stood at $35.27 million compared to revenue of $154.08 million.
Earnings Surprise
For the three-month period that ended June 29, Adma Biologics Inc had $140.31 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$6.37 million in the quarter, while revenues of -$6.79 million were shrunk -116.01%. The analyst consensus anticipated Adma Biologics Inc’s latest quarter earnings to come in at -$0.02 per share, but it turned out to be -$0.03, a -50.00% surprise. For the quarter, EBITDA amounted to $2.28 million. Shareholders own equity worth $224.91 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Adma Biologics Inc (ADMA) price momentum. RSI 9-day as of the close on 29 September was 40.70%, suggesting the stock is Neutral, with historical volatility in this time frame at 21.95%.
As of today, ADMA’s price is $3.55 +1.99% or $0.07 from its 5-day moving average. ADMA is currently trading -7.01% lower than its 20-day SMA and +2.29% higher than its 100-day SMA. However, the stock’s current price level is -4.79% below the SMA50 and -1.92% below the SMA200.
The stochastic %K and %D were 28.12% and 24.39%, respectively, and the average true range (ATR) was 0.12. With the 14-day stochastic at 30.21% and the average true range at 0.13, the RSI (14) stands at 40.57%. The stock has reached 0.01 on the 9-day MACD Oscillator while the 14-day reading was at -0.06.
Analyst Ratings
The consensus rating for Adma Biologics Inc (ADMA) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ADMA, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.
What is ADMA’s price target for the next 12 months?
Analysts predict a range of price targets between $5.00 and $7.00, with a median target of $6.00. Taking a look at these predictions, the average price target given by analysts for Adma Biologics Inc (ADMA) stock is $6.00.
